Ingrezza access in Saudi Arabia

A patient-first orientation

Ingrezza is the brand name for valbenazine, an oral small-molecule selective vesicular monoamine transporter 2 (VMAT2) inhibitor manufactured by Neurocrine Biosciences. By selectively inhibiting VMAT2 in the nigrostriatal pathway, valbenazine dampens the hyperkinetic, involuntary movements that characterize both tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The US Food and Drug Administration approved Ingrezza on April 11, 2017 for adults with tardive dyskinesia, the first medication ever approved in the United States for that condition, and on August 18, 2023 for adults with chorea associated with Huntington's disease. The Saudi Food and Drug Authority has not registered valbenazine, and neither EMA, MHRA, PMDA Japan, nor Health Canada have approved it for local marketing. For Saudi families whose psychiatrist or neurologist has identified Ingrezza as the right next step, the lawful route into the Kingdom is the SFDA Personal Importation Program. Reserved for you.

Why Saudi patients need Ingrezza through the named-patient pathway

Tardive dyskinesia and Huntington's chorea are both undertreated globally. TD develops in a meaningful fraction of patients on long-term antipsychotic therapy, including patients managed inside the Saudi public-sector psychiatry system at KFSH&RC, KAMC, and the Ministry of Health network. When the condition is recognized, the prescriber's options are narrow: dose reduction of the causative antipsychotic (which can destabilize the underlying psychiatric condition), tetrabenazine (older, nonselective, heavier side-effect burden), or a VMAT2 inhibitor like valbenazine that the local market does not stock. Huntington's disease in Saudi Arabia is rare and concentrated in a small number of specialist neurology clinics, and HD chorea management with selective VMAT2 inhibition is a relatively new option that simply has not reached local pharmacy formularies.

The structural reason both populations reach for Ingrezza through PIP is the same: no local registration anywhere in the GCC, no commercial agent, and no alternative VMAT2 inhibitor stocked routinely. Reserve Meds approaches both indications with the respect the conditions deserve. We do not describe TD as a "side effect to live with" and we do not describe Huntington's chorea as something to be managed without recognizing the family-wide weight of the diagnosis.

The SFDA Personal Importation Program for Ingrezza

The SFDA Personal Importation Program allows a Saudi-licensed physician to request import of a specific medicine for a specific named patient when the medicine is approved by a recognized reference authority and a clinically equivalent locally registered alternative is not suitable. Applications are filed through the dispensing institution's import pharmacy and reviewed by SFDA's Drug Sector.

The application package contains the clinical justification letter from the treating physician, treating physician SCFHS licensing verification (in the relevant specialty: psychiatry for TD, neurology for HD), the patient identifier, product details (brand name, INN, manufacturer, country of origin, strength, dosage form, pack size, requested quantity, lot, expiry), the destination dispensing facility license, and the chain-of-custody plan.

For Ingrezza specifically, the clinical justification letter has two distinct angles depending on indication. For tardive dyskinesia, the letter documents the diagnosis with reference to the causative dopamine receptor blocking agent (antipsychotic or specific antiemetic), the duration of prior exposure, the severity of involuntary movements measured by a validated instrument such as the Abnormal Involuntary Movement Scale (AIMS), and the prescriber's clinical judgment that dose reduction of the causative agent is not feasible without destabilizing the underlying psychiatric condition. For Huntington's chorea, the letter documents the genetic confirmation (CAG repeat expansion test result), the Unified Huntington's Disease Rating Scale chorea subscale score, the prior trial of any other movement-management strategy, and a confirmed acknowledgment of the boxed warning for depression and suicidality applicable to the HD indication. The latter point is non-optional: Reserve Meds requires the boxed-warning acknowledgment in the case file before initiating sourcing.

Approval timelines for routine cases run 10 to 21 business days. Ingrezza files for TD typically run inside the routine band. HD chorea files can extend into the complex range (6 to 10 weeks) if the prescriber is new to the file or if SFDA wants additional confirmation of the genetic diagnosis or the suicidality monitoring plan.

Where Ingrezza gets dispensed in Saudi Arabia

Because Ingrezza is an oral capsule with no cold-chain requirement, it can be dispensed by any SFDA-licensed import pharmacy. For TD cases, the practical hubs are the psychiatry departments at KFSH&RC, King Abdulaziz Medical City, KSUMC, Dr. Sulaiman Al Habib Medical Group (HMG), and the academic medical center psychiatry programs in Riyadh and Jeddah. For HD cases, the neurology departments at KFSH&RC and KAMC, which carry the genetic counseling and HD-specialist capability, are the dominant entry points. Patients outside the major tertiary centers route through an SFDA-licensed specialty importer in Riyadh or Jeddah, with the drug then transferred to the local dispensing facility under the institutional license. The Ingrezza Sprinkle formulation, supplied in unit-dose packets for patients with swallowing difficulty, can be requested specifically and follows the same PIP pathway.

Real cost picture for Ingrezza in Saudi Arabia

US wholesale acquisition cost references in 2026 cite a 28-capsule bottle of 40 mg at roughly USD 7,900 and 80 mg at roughly USD 8,700, working out to an approximate annual list-price range of USD 103,000 to USD 113,000 at maintenance dosing of 80 mg once daily. At the Saudi Riyal peg of approximately 3.75 SAR per USD, the annual drug cost at maintenance dose is approximately SAR 386,000 to SAR 424,000 at US WAC.

The Reserve Meds firm quote line-items the drug cost at WAC plus standard procurement margin, the international logistics in the SAR 1,500 to SAR 3,000 range (Ingrezza is ambient and ships easily), and the concierge coordination fee. Because both TD and HD chorea are chronic conditions on continuous therapy, the meaningful financial planning horizon is annual rather than per-bottle. Reserve Meds quotes monthly refill cycles to make the cash-flow picture predictable. Bupa Arabia, Tawuniya, and MedGulf Arabia handle named-patient imports case-by-case; for chronic neurology and psychiatry indications with documented prior therapy failures, some plans engage in case-specific reimbursement discussions, though cash-pay remains the default operating posture. Neurocrine's US patient access programs (INBRACE copay, patient assistance) are US-resident-only and do not extend to international patients.

Typical timeline for Ingrezza in Saudi Arabia

From a complete PIP application filing, routine TD cases run 10 to 21 business days at SFDA. HD chorea cases can extend toward the 6-to-10-week range if SFDA requests additional confirmation of the genetic diagnosis or the suicidality monitoring plan. Reserve Meds aligns US-side sourcing through Neurocrine's specialty pharmacy network in parallel; because Ingrezza is gated to specialty channels rather than open wholesale, the US-side procurement leg can add 2 to 5 business days versus an open-distribution drug. The international shipping leg runs 3 to 7 business days. End-to-end, a typical TD case completes inside 5 to 7 weeks and a typical HD case can run 8 to 12 weeks from documentation intake to first dose available.

What your physician needs to provide

The clinical justification letter from the SCFHS-licensed treating physician (psychiatrist for TD, neurologist for HD) addresses the diagnosis with ICD-10 coding, the severity measured by a validated instrument (AIMS for TD, UHDRS chorea subscale for HD), the documented sequence of prior therapy attempts, the rationale for valbenazine specifically over deutetrabenazine or tetrabenazine, and the proposed dosing per the FDA-approved label. For TD: start 40 mg once daily, increase to 80 mg once daily after one week (40 mg or 60 mg may be considered for patients who do not tolerate 80 mg). For HD chorea: start 40 mg once daily, titrate weekly in 20 mg increments based on chorea reduction, tolerability, and clinical assessment, up to a maximum 80 mg once daily. The letter should reference the CYP3A4 and CYP2D6 interaction profile (dose reduction required for strong CYP3A4 or CYP2D6 inhibitors and for known CYP2D6 poor metabolizers, with maximum 40 mg once daily in those settings), and for HD cases include an explicit acknowledgment of the boxed warning for depression and suicidality and a defined plan for baseline and ongoing mood and suicidality assessment with caregiver involvement.

Common questions about Ingrezza in Saudi Arabia

Will Bupa Arabia, Tawuniya, or MedGulf cover this? Each plan handles named-patient imports case-by-case. For chronic psychiatric and neurological indications with documented prior therapy failures, some plans engage in case-specific reimbursement discussions; many require pre-authorization. Cash-pay is the default operating posture.

Will my Ministry of Health-employed psychiatrist's letter be sufficient? Yes. KSA-licensed psychiatrists and neurologists at MoH hospitals, KFSH&RC, KAMC, MNGHA, and other public-sector institutions have full PIP signing authority. Private-sector specialists at HMG, Saudi German, Fakeeh, and Dallah sign under their institutional license.

What about the HD boxed warning? The FDA label for valbenazine in the Huntington's chorea indication carries a boxed warning for depression and suicidality, reflecting the underlying psychiatric vulnerability of the HD population. The treating neurologist must acknowledge this warning in the PIP file and define a plan for baseline and ongoing mood and suicidality assessment, with caregivers and clinicians both involved. Reserve Meds includes this acknowledgment template in the documentation kit and will not proceed without it for HD cases.

What is the safety profile? Beyond the HD-specific boxed warning, the most commonly reported adverse reaction is somnolence. Other notable warnings include QT prolongation, parkinsonism (including hypokinesia and rigidity), and neuroleptic malignant syndrome. Baseline and ongoing assessment of mood, sedation, and emergent parkinsonism is appropriate for both indications.

Why Ingrezza versus deutetrabenazine? Once-daily dosing is the most cited practical advantage of valbenazine; deutetrabenazine is dosed twice daily with food. The choice is a clinical decision made by the treating specialist. Reserve Meds does not advise patients on which VMAT2 inhibitor to use; that conversation belongs with the treating neurologist or psychiatrist.

Can the dose be split or stopped abruptly? Capsules should be taken whole unless the Sprinkle formulation is prescribed. The label does not require gradual taper, but any change to therapy should be made by the prescribing clinician.

Where Reserve Meds fits in Ingrezza cases

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, SFDA, or your dispensing pharmacy. We orchestrate US-side sourcing through Neurocrine's specialty pharmacy network, prepare the SFDA-aligned documentation kit your physician needs (with the HD boxed-warning acknowledgment template where applicable), coordinate international logistics through standard ambient pharmaceutical air-freight, and assign a single named coordinator who stays with the case from intake through monthly reorders. Because both TD and HD chorea are chronic indications on indefinite therapy, the coordinator relationship is a long one. Reserve Meds approaches every Ingrezza file with the respectful psychiatric and neurological vocabulary the conditions warrant, and treats the families involved as the decision-makers they are.

Next step

Join the Ingrezza waitlist for Saudi Arabia

Reserved for you.